Despite significant advancements in CRC treatment, distant metastasis remains the leading cause of mortality, intermittently driven by treatment resistance linked to genetic mutations in KRAS, BRAF, and PIK3CA, which alter disease progression [18]. Here, KRAS is linked to colorectal carcinoma.